DEFENCE THERAPEUTICS
ACCUMTM
VARIANTS IN VITRO STUDY INCREASES
THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST
CANCER
Vancouver, BC,
Canada, October 13th,
2021 --
InvestorsHub NewsWire -- Defence Therapeutics
Inc. CSE:DTC, USOTC:DTCFF, ("Defence"
or the "Company"),
a biotechnology company working on cancer therapeutics and
infectious disease vaccines is pleased to announce strong
in
vitro results of its
AccumTM
variants on the recent
Enhertu® (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca
and Daiichi Sankyo.
Defence has successfully selected and tested 5
AccumTM
variants to the T-deruxtecan ADC Therapeutic. The 5 selected
Accum-T-deruxtecan increases the potency of T-deruxtecan ADC
Therapeutic by approximatively 5-fold on the HER2 positive breast
cancer Trastuzumab and T-DM1 resistant cell line model named
JIMT-1. At concentration of 0.001 ug/ml, T-deruxtecan only induce
approximatively 13% of cytotoxicity comparatively to the 5
Accum-T-deruxtecan variants that increase the cytotoxicity by
21-37%.
The 5
selected
AccumTM
variants will be sent to our
collaborator at the HUS Comprehensive Cancer Center in Helsinki,
Finland for the optimization of Defence's Accum-T-deruxtecan ADC
Therapeutic.
Defence's
AccumTM
platform has been
developed and tested in vitro
to enhance the
intracellular drug delivery on multiple ADCs that are FDA approved
or under development.
The AccumTM
technology platform is very efficient at enhancing intracellular
delivery of proteins of pharmacological interests such as ADCs or
vaccine antigens.
"The strong results confirmed the expectation of our scientific
team that the AccumTM
can increase the routing
and delivery of the T-deruxtecan to the nucleus and consequently
increased more significantly the potency of the
ADC.
That confirms also and again the strength and
optimization of our AccumTM platform
in the ADC field of therapeutics against cancer and the solid
competitive advantage we have with our AccumTM
variants
derived from our AccumTM
technology platform", says Mr. Sebastien Plouffe, CEO of Defence
Therapeutics.
According to Facts and Factors market research report, the Global
Breast Cancer Treatment Market size & share revenue is expected
to grow from USD 19.24 Billion in 2019 to reach USD 34.06 Billion
by 2026, at 8.5% annual CAGR growth during forecast period of
2021-2026.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.
